Prescribing, dispensing, hospital activity and prevalence are all published, at a level of detail that answers real commercial questions. The work is not finding the data. It is building the layer underneath that makes it joinable, current and trustworthy enough to put in front of a board.
Most NHS data work is done once, in a spreadsheet, by someone who then leaves. Three months later the numbers are stale, nobody can reproduce them, and the analysis is repeated from scratch.
We run it as a platform instead. A governed data layer built from published NHS sources, refreshed on a schedule, with a consistent schema and analytics engine, sitting under a front end your team uses directly, with your branding on it. Proprietary lock in and no per seat pricing that punishes you for sharing insight internally.
The value sits in the data universe underneath rather than anything on the surface. Activity at Practices, trusts, PCNs and ICBs reconciled against reference data. Definitions held steady so that a count means the same thing in every view. History retained, so you can see movement rather than a snapshot.
What sits on top is deliberately ordinary. Insights your team opens without asking anyone, filters that behave the way people expect, and the ability to put a new question to it and get an answer worth taking into a meeting. Real questions, real published data, and a number that holds up when somebody challenges it.
Published NHS sources, modelled and joined so that a question spanning several of them takes moments rather than a fortnight.
Every item dispensed in primary care in England, by practice, by month. Volume, cost and quantity at the level that lets you see real prescribing behaviour rather than a national average.
Medicines issued by NHS trusts. The hospital half of the picture, and the half most commercial teams are missing when they model a product with a hospital initiation and a primary care tail.
Community pharmacy dispensing alongside Advanced Services including Pharmacy First. Useful wherever the pharmacy channel is part of the pathway rather than an afterthought.
Admissions, outpatient attendances and procedures. Where you go when the question is about the patient pathway rather than the product.
Practice level prevalence and achievement across long term conditions. The denominator that turns a prescribing count into a market share.
The reference data that makes everything else joinable. Practices, trusts, PCNs, ICBs and how they roll up. Unglamorous, and nothing works without it.
National totals hide everything. The useful view is by ICB, by PCN, by practice, and how that has moved over the last twenty four months.
Launch trajectories, switching between products in a class, and whether growth is new patients or moved ones.
Ranked targets built from prescribing behaviour and prevalence rather than from who happened to answer the phone.
Products initiated in secondary care and continued in primary care are invisible in either dataset alone. Together they are not.
Before and after views at the level the decision was actually made, rather than an anecdote from the field team.
Prevalence and achievement data turned into a denominator you can defend in a business case.
The platform is licensed monthly, and the licence comes with a fixed allocation of our time each month. That covers the analysis, the new questions, the additions to the model and the presales support when you are taking insight to your own clients.
Typically run as a six month initial term so both sides can see whether it is earning its keep before anyone commits further.
Pharma commercial and market access teams who need regional detail rather than a national headline. Small consultancies who want a data capability without building a data team. Health tech companies whose product needs a market picture in front of an investor.
We will tell you whether the published data can answer it, roughly what it would take, and whether it is worth doing.